Clinical Trials Sponsored by Vanesa Abuín

Total 283 results

Vanesa Abuín
Universidad Europea de Madrid

Completed

Effectiveness of the Neural Mobilization on Upper Limb Functionality in Patients With Acquired Brain Injury

Acquired Brain Injury | Hemiplegia and Hemiparesis

Spain
University of Jyvaskyla
Vanha Vaasa Hospital

Recruiting

The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Psychotic Depression | Delusional Disorder

Finland
Vantia Ltd

Completed

VA106483 Dose Response Study in Elderly Males

Nocturia

United States
Vantia Ltd

Completed

Dose Range Finding Study of Fedovapagon in Men With Nocturia

Nocturia

United States
Vantia Ltd

Completed

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

Primary Dysmenorrhea

United States, United Kingdom
Saneso Inc.

Completed

Case Series With Saneso 3600 Colonoscope

Colonic Neoplasms

United States
Vantia Ltd

Completed

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC)

Nocturia

United States
Vantia Ltd

Completed

A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval

Healthy

Germany
Vantia Ltd

Completed

Efficacy Study of VA106483 in Males With Nocturia.

Nocturia

United States
Vantia Ltd

Completed

VA106483 Dose Response in Females

Nocturia

United States
Vantia Ltd

Completed

VA106483 and Alpha Blocker Interaction Study in Elderly Males

Nocturia

United Kingdom
Kanisa Pharmaceuticals

Completed

Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid
Vanessa Olbrecht

Enrolling by invitation

Recruitment and Behavioral Economic Strategies

Surgery | Adolescent Behavior

United States
Vantia Ltd

Completed

Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon

Nocturia

Germany
Vantia Ltd

Completed

Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)

Nocturia | Benign Prostatic Hypertrophy (BPH)

Germany
Vantia Ltd

Completed

VA111913 TS: First in Human Study

Dysmenorrhea

United Kingdom
Kanisa Pharmaceuticals

Completed

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Leukemia, Myeloid
Valneva Austria GmbH

Recruiting

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Zika | Zika Virus Infection

United States
Valneva Austria GmbH

Completed

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 (COV-COMPARE)

SARS-CoV-2 Virus Infection

United Kingdom
Valneva Austria GmbH

Active, not recruiting

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Chikungunya

United States
Kaneka Corporation
ClinSearch

Unknown

Post Market Clinical Follow-Up for ED Coil / Electro-detach Generator v4

Arteriovenous Malformations | Aneurysm | Arterio-venous Fistula

Germany, Belgium
Valneva Austria GmbH

Completed

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Japanese Encephalitis

Germany, Austria
Valneva Austria GmbH

Completed

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

Healthy

Austria, Germany
Valneva Austria GmbH

Completed

This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population

Japanese Encephalitis

Germany, Austria
Vanda Pharmaceuticals

Recruiting

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Dry Eye

United States
Vanda Pharmaceuticals

Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

Sleep Wake Disorders | Sleep Disorders, Circadian Rhythm | Chronobiology Disorders

United States, Australia, Germany
Vanda Pharmaceuticals

Completed

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

Treatment-resistant Pruritus Associated With Atopic Dermatitis

Germany
Vanda Pharmaceuticals

Completed

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Bipolar I Disorder

United States, Bulgaria, Poland
Vanda Pharmaceuticals

Active, not recruiting

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Non 24 Hour Sleep Wake Disorder

France
Vanda Pharmaceuticals

Completed

Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents

Autism Spectrum Disorder | Smith-Magenis Syndrome | Non-24 Hour Sleep-Wake Disorder | Circadian Rhythm Sleep Disorders

United States
Vanda Pharmaceuticals

Available

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Gastroparesis | Diabetic Gastroparesis

United States
Vanda Pharmaceuticals

Completed

Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia

Jet Lag Type Insomnia

United States
Vanda Pharmaceuticals

Unknown

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Coronavirus Infection

United States
Vanda Pharmaceuticals

Unknown

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Relapsed or Refractory Hematologic Malignancies

United States
Vanda Pharmaceuticals

Unknown

Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)

Smith Magenis Syndrome

United States
Vanda Pharmaceuticals

Completed

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
Vanda Pharmaceuticals

Completed

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

Healthy Volunteers

United States
Vanda Pharmaceuticals

Completed

Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol

Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol

Canada
Valneva Austria GmbH

Recruiting

A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years

Chikungunya Virus Infection

Dominican Republic, Honduras
Valneva Austria GmbH

Completed

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Japanese Encephalitis
Valneva Austria GmbH

Completed

Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years

SARS-CoV-2 Virus Infection

New Zealand
Valneva Austria GmbH

Completed

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Chikungunya Virus Infection

United States
Valneva Austria GmbH

Completed

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Encephalitis

Philippines
Valneva Austria GmbH

Completed

Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries

Encephalitis

United States, Australia, Denmark, Germany, Sweden

3

Subscribe